Dicerna Stock Today

DRNA -  USA Stock  

USD 37.38  0.13  0.35%

Dicerna Pharmaceutic is trading at 37.38 as of the 2nd of August 2021, a -0.35 percent decrease since the beginning of the trading day. The stock's open price was 37.51. Dicerna Pharmaceutic has a very small chance of experiencing financial distress in the next few years and had a ok performance during the last 90 days. Equity ratings for Dicerna Pharmaceutic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of August 2019 and ending today, the 2nd of August 2021. Click here to learn more.
 Market Performance
10 of 100
  Odds Of Distress
Less than 1

Dicerna Pharmaceutic Stock Profile

The upcoming quarterly report is expected on the 5th of August 2021. Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. more on Dicerna Pharmaceutic
Dicerna Pharmaceutic has very high historical volatility over the last 90 days
Dicerna Pharmaceutic is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 177.88 M. Net Loss for the year was (120.22 M) with loss before overhead, payroll, taxes, and interest of (41.08 M).
Dicerna Pharmaceutic currently holds about 544.88 M in cash with (172.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.09.
Dicerna Pharmaceutic has a poor financial position based on the latest SEC disclosures
Over 85.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.equities.com: Dicerna gains 0.97 percent on Moderate Volume July 30 - Equities.com
Dicerna Pharmaceutic Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Dicerna Pharmaceutic SEC Filings
Dicerna Pharmaceutic SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDicerna Pharmaceutic
President CEO, DirectorDouglas Fambrough  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Dicerna Pharmaceutic report their recommendations after researching Dicerna Pharmaceutic's financial statements, talking to executives and customers, or listening in on Dicerna Pharmaceutic's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dicerna Pharmaceutic. The Dicerna consensus assessment is calculated by taking the average forecast from all of the analysts covering Dicerna Pharmaceutic.
Strong Buy7 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Dicerna Pharmaceutic based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Dicerna Pharmaceutic financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares80 M74.2 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted80 M74.2 M
Significantly Up
Slightly volatile
Net Cash Flow from Operations188.9 M175.1 M
Significantly Up
Slightly volatile
Total Assets763.7 M707.8 M
Significantly Up
Slightly volatile
Total Liabilities615.1 M570.1 M
Significantly Up
Slightly volatile
Current Assets667.5 M618.7 M
Significantly Up
Slightly volatile
Current Liabilities192 M177.9 M
Significantly Up
Slightly volatile
Total Debt56.3 M52.2 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Asset Turnover0.250.227
Significantly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Dicerna Pharmaceutic's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldFairly Valued
Financial Strength
Dicerna Pharmaceutic's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Dicerna Pharmaceutic's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dicerna Pharmaceutic's financial leverage. It provides some insight into what part of Dicerna Pharmaceutic's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Dicerna Pharmaceutic's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Dicerna Pharmaceutic deploys its capital and how much of that capital is borrowed.
Dicerna Pharmaceutic cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 51.64 M in liabilities with Debt to Equity (D/E) ratio of 0.41, which is about average as compared to similar companies. Dicerna Pharmaceutic has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

188.94 MillionShare
Dicerna Pharmaceutic (DRNA) is traded on NASDAQ Exchange in USA. It is located in 75 Hayden Avenue, Lexington, MA 02421, United States and employs 302 people. Dicerna Pharmaceutic is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dicerna Pharmaceutic's market, we take the total number of its shares issued and multiply it by Dicerna Pharmaceutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Dicerna Pharmaceutic conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 76.9 M outstanding shares of which 5.08 M shares are currently shorted by private and institutional investors with about 7.04 trading days to cover. Dicerna Pharmaceutic currently holds about 544.88 M in cash with (172.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.09.
Check Dicerna Pharmaceutic Probability Of Bankruptcy
Dicerna Pharmaceutic retains a total of 76.9 Million outstanding shares. The majority of Dicerna Pharmaceutic outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dicerna Pharmaceutic to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dicerna Pharmaceutic. Please pay attention to any change in the institutional holdings of Dicerna Pharmaceutic as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Dicerna Ownership Details

Dicerna Stock Price Odds Analysis

What are Dicerna Pharmaceutic's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Dicerna Pharmaceutic jumping above the current price in 90 days from now is about 20.01%. The Dicerna Pharmaceutic probability density function shows the probability of Dicerna Pharmaceutic stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Dicerna Pharmaceutic has a beta of -0.5354 suggesting as returns on benchmark increase, returns on holding Dicerna Pharmaceutic are expected to decrease at a much lower rate. During the bear market, however, Dicerna Pharmaceutic is likely to outperform the market. Additionally, the company has an alpha of 0.3691, implying that it can generate a 0.37 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 37.38HorizonTargetOdds Up 37.38 
79.90%90 days
Based on a normal probability distribution, the odds of Dicerna Pharmaceutic to move above the current price in 90 days from now is about 20.01 (This Dicerna Pharmaceutic probability density function shows the probability of Dicerna Stock to fall within a particular range of prices over 90 days) .

Dicerna Pharmaceutic Historical Income Statement

Dicerna Pharmaceutic Income Statement is one of the three primary financial statements used for reporting Dicerna's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dicerna Pharmaceutic revenue and expense. Dicerna Pharmaceutic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Dicerna Pharmaceutic Gross Profit is projected to increase significantly based on the last few years of reporting. The past year's Gross Profit was at 164.31 Million. The current year Interest Expense is expected to grow to about 20.5 K, whereas Consolidated Income is forecasted to decline to (115.7 M). View More Fundamentals

Dicerna Stock Against Markets

Picking the right benchmark for Dicerna Pharmaceutic stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dicerna Pharmaceutic stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dicerna Pharmaceutic is critical whether you are bullish or bearish towards Dicerna Pharmaceutic at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dicerna Pharmaceutic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Directory Now


ETF Directory

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Dicerna Pharmaceutic Corporate Directors

Dicerna Pharmaceutic corporate directors refer to members of a Dicerna Pharmaceutic board of directors. The board of directors generally takes responsibility for the Dicerna Pharmaceutic's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Dicerna Pharmaceutic's board members must vote for the resolution. The Dicerna Pharmaceutic board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Bruce Peacock - Independent DirectorProfile
Dennis Langer - Independent DirectorProfile
Martin Freed - Independent DirectorProfile
Kevin Buchi - Independent DirectorProfile
Continue to Investing Opportunities. Note that the Dicerna Pharmaceutic information on this page should be used as a complementary analysis to other Dicerna Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Dicerna Stock analysis

When running Dicerna Pharmaceutic price analysis, check to measure Dicerna Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dicerna Pharmaceutic is operating at the current time. Most of Dicerna Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Dicerna Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dicerna Pharmaceutic's price. Additionally, you may evaluate how the addition of Dicerna Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
The market value of Dicerna Pharmaceutic is measured differently than its book value, which is the value of Dicerna that is recorded on the company's balance sheet. Investors also form their own opinion of Dicerna Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Dicerna Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dicerna Pharmaceutic's market value can be influenced by many factors that don't directly affect Dicerna Pharmaceutic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dicerna Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Dicerna Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dicerna Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.